

Global Graves Ophthalmopathy Treatment Market - 2025 -2033

<https://marketpublishers.com/r/G4AB36F4B952EN.html>

Date: October 2025

Pages: 180

Price: US\$ 4,350.00 (Single User License)

ID: G4AB36F4B952EN

Abstracts

Market Size

The global graves ophthalmopathy treatment market size reached US\$ 2.09 Billion in 2024 and is expected to reach US\$ 3.01 Billion by 2033, growing at a CAGR of 4.2% during the forecast period 2025-2033.

Market Overview

The Graves ophthalmopathy treatment market is experiencing a significant transformation, driven by advancements in treatment options with strong pipeline products, increasing disease awareness and growing global incidence. For instance, according to the study conducted by the National Institutes of Health, Graves' ophthalmopathy is clinically relevant in 25-50% of patients with Graves' disease and 2% of patients with chronic thyroiditis. The age-adjusted annual incidence of clinically relevant GO is 16 per 100,000 population in women and 2.9 in men. At the onset of ophthalmopathy, 80-90% of patients have hyperthyroidism, with the rest having euthyroidism or hypothyroidism. This consistent incidence and disease overlap with common thyroid disorders sustain long-term market growth.

Pipeline innovation is robust, with companies like Viridian Therapeutics, Immunovant and Argenx, among others, developing next-generation biologics, aiming to reduce cost, increase convenience and improve safety profiles. These formats are expected to penetrate underserved and outpatient markets.

Market Dynamics

Drivers:

The rising pipeline products are significantly driving the market growth

Historically, treatment options were limited to high-dose corticosteroids, radiation or surgery, often with suboptimal outcomes and relapse rates exceeding 30–40%. The approval of Tepezza (teprotumumab) in 2020 marked the first targeted biologic therapy and opened the floodgates for R&D investment in TED. However, Tepezza's limitations, IV-only administration, high cost (\$14,900 per vial) and side effects like hearing impairment created an opportunity for innovation. This has accelerated the development of next-generation therapies that are subcutaneous, oral or have novel mechanisms of action.

The growing pipeline products are a major growth driver for the Graves ophthalmopathy treatment market, as they address the unmet needs left by traditional therapies and expand access to more patients globally. For instance, in January 2025, Sling Therapeutics, Inc. announced topline efficacy and safety data from the Phase 2b/3 LIDS trial of linsitinib in patients with active, moderate to severe TED. Similarly, in May 2025, Viridian Therapeutics, Inc. announced that the United States Food and Drug Administration (FDA) granted Breakthrough Therapy Designation to veligrotug, the company's lead anti-insulin-like growth factor-1 receptor (IGF-1R) drug candidate for the treatment of TED.

Restraints:

A limited number of approved therapies is hampering the Market growth

The limited number of approved therapies is a significant constraint on the growth of the Graves' Ophthalmopathy treatment market, primarily because it restricts patient access, physician choice, and innovation in care strategies. As of now, Tepezza (teprotumumab), approved by the U.S. FDA in 2020, remains the only targeted biologic therapy specifically indicated for the disease. While Tepezza has demonstrated notable efficacy, its high cost, intravenous-only administration, and potential side effects make it unsuitable for all patient profiles.

This therapeutic bottleneck becomes even more problematic in regions outside the U.S., where regulatory approvals lag and access is limited or nonexistent. Patients in Europe and Asia often still rely on non-specific treatments like corticosteroids, radiation, or invasive surgeries, which offer inconsistent outcomes and higher complication risks.

Segmentation Analysis

The global Graves ophthalmopathy treatment market is segmented based on medication, disease severity, end-user, and region.

The monoclonal antibodies from the medication segment are dominating the Graves ophthalmopathy treatment market with a 34.43% share in 2024

Monoclonal antibodies (mAbs) are currently dominating the Graves' ophthalmopathy treatment market due to their targeted mechanism of action, high efficacy, and growing clinical preference for biologics over traditional therapies. The most prominent instance is Tepezza (teprotumumab), a monoclonal antibody targeting the insulin-like growth factor-1 receptor (IGF-1R), which plays a key role in Graves ophthalmopathy pathogenesis. Approved by the U.S. FDA in 2020, Tepezza is the first and only approved therapy specifically designed for the disease. Its success has revolutionized treatment standards, delivering rapid improvement in proptosis, diplopia, and quality of life for moderate to severe patients.

Tepezza's commercial performance demonstrates the dominance of mAbs in this space. With high unmet need and lack of competition, mAbs are filling a crucial therapeutic gap. Additionally, new pipeline candidates, such as Viridian's veligrotug (VRDN-001) and Sling Therapeutics' linsitinib, though not all are mAbs, are targeting similar pathways, further reinforcing the biologics trend. Physicians are increasingly moving away from broad-spectrum immunosuppressants like corticosteroids, favoring mAbs for their predictable efficacy and reduced long-term toxicity.

Geographical Shares

North America is expected to dominate the global Graves ophthalmopathy treatment market with a 42.73% in 2024

North America, particularly the United States, is the dominant region in the global Graves ophthalmopathy treatment market, driven by early adoption of advanced therapies, strong healthcare infrastructure, and significant R&D investment. The region accounts for a major share of global revenue, largely due to the commercial success of Tepezza (teprotumumab), the first and only FDA-approved drug. Approved in 2020, Tepezza rapidly became a blockbuster.

The U.S. also leads in clinical trials and regulatory approvals, as seen in the development of pipeline candidates like veligrotug (Viridian Therapeutics) and linsitinib (Sling Therapeutics), both advancing rapidly through FDA-supported studies.

Competitive Landscape

Top companies in the Graves ophthalmopathy treatment market include Amgen Inc., Immunovant, Inc., Viridian Therapeutics, Inc., Argenx, Tourmaline Bio, Inc., F. Hoffmann-La Roche Ltd and Sling Therapeutics, among others.

The global Graves ophthalmopathy treatment market report delivers a detailed analysis with 53 key tables, more than 51 visually impactful figures, and 167 pages of expert insights, providing a complete view of the market landscape.

Contents

1. MARKET INTRODUCTION AND SCOPE

- 1.1. Objectives of the Report
- 1.2. Report Coverage & Definitions
- 1.3. Report Scope

2. EXECUTIVE INSIGHTS AND KEY TAKEAWAYS

- 2.1. Market Highlights and Strategic Takeaways
- 2.2. Key Trends and Future Projections
- 2.3. Snippet by Medication
- 2.4. Snippet by Disease Severity
- 2.5. Snippet by End-User
- 2.6. Snippet by Region

3. DYNAMICS

- 3.1. Impacting Factors
 - 3.1.1. Drivers
 - 3.1.1.1. Rising Pipeline Products
 - 3.1.1.2. Introduction & Success of Targeted Biologic Therapies (Teprotumumab)
 - 3.1.2. Restraints
 - 3.1.2.1. Limited Number of Approved Therapies
 - 3.1.2.2. Side Effects and Safety Concerns
 - 3.1.3. Opportunity
 - 3.1.3.1. Strong Investor & Pharma Interest in Rare Autoimmune Niches
 - 3.1.3.2. Mergers, Acquisitions & Strategic Partnerships
 - 3.1.4. Impact Analysis

4. STRATEGIC INSIGHTS AND INDUSTRY OUTLOOK

- 4.1. Market Leaders and Pioneers
 - 4.1.1. Emerging Pioneers and Prominent Players
 - 4.1.2. Established Leaders with the Largest Marketing Brand
 - 4.1.3. Market Leaders with Established Products
- 4.2. Latest Developments and Breakthroughs
- 4.3. Regulatory and Reimbursement Landscape

- 4.3.1. North America
- 4.3.2. Europe
- 4.3.3. Asia Pacific
- 4.3.4. South America
- 4.3.5. Middle East & Africa
- 4.4. Porter's Five Forces Analysis
- 4.5. Patent Analysis
- 4.6. SWOT Analysis
- 4.7. Unmet Needs and Gaps
- 4.8. Recommended Strategies for Market Entry and Expansion
- 4.9. Pricing Analysis and Price Dynamics

5. GRAVES OPHTHALMOPATHY TREATMENT MARKET, BY MEDICATION

- 5.1. Introduction
 - 5.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Medication
 - 5.1.2. Market Attractiveness Index, By Medication
- 5.2. Monoclonal Antibodies*
 - 5.2.1. Introduction
 - 5.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
 - 5.2.3. Teprotumumab
 - 5.2.4. Batoclimab
 - 5.2.5. Others
- 5.3. Corticosteroids
 - 5.3.1. Prednisolone
 - 5.3.2. Dehydrocortisone
 - 5.3.3. Others
- 5.4. Antithyroid Medications
 - 5.4.1. Propylthiouracil
 - 5.4.2. Methimazole
 - 5.4.3. Others
- 5.5. Others

6. GRAVES OPHTHALMOPATHY TREATMENT MARKET, BY DISEASE SEVERITY

- 6.1. Introduction
 - 6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Severity
 - 6.1.2. Market Attractiveness Index, By Disease Severity
- 6.2. Mild*

- 6.2.1. Introduction
- 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 6.3. Moderate
- 6.4. Severe

7. GRAVES OPHTHALMOPATHY TREATMENT MARKET, BY END-USER

- 7.1. Introduction
 - 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
 - 7.1.2. Market Attractiveness Index, By End-User
- 7.2. Hospitals*
 - 7.2.1. Introduction
 - 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 7.3. Specialty Clinics
- 7.4. Academic and Research Institutes
- 7.5. Others

8. GRAVES OPHTHALMOPATHY TREATMENT MARKET, BY REGIONAL MARKET ANALYSIS AND GROWTH OPPORTUNITIES

- 8.1. Introduction
 - 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
 - 8.1.2. Market Attractiveness Index, By Region
- 8.2. North America
 - 8.2.1. Introduction
 - 8.2.2. Key Region-Specific Dynamics
 - 8.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Medication
 - 8.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Severity
 - 8.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
 - 8.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
 - 8.2.6.1. U.S.
 - 8.2.6.2. Canada
 - 8.2.6.3. Mexico
- 8.3. Europe
 - 8.3.1. Introduction
 - 8.3.2. Key Region-Specific Dynamics
 - 8.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Medication
 - 8.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Severity
 - 8.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

8.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country

8.3.6.1. Germany

8.3.6.2. UK

8.3.6.3. France

8.3.6.4. Spain

8.3.6.5. Italy

8.3.6.6. Rest of Europe

8.4. Asia-Pacific

8.4.1. Introduction

8.4.2. Key Region-Specific Dynamics

8.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Medication

8.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Severity

8.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

8.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country

8.4.6.1. China

8.4.6.2. India

8.4.6.3. Japan

8.4.6.4. South Korea

8.4.6.5. Rest of Asia-Pacific

8.5. South America

8.5.1. Introduction

8.5.2. Key Region-Specific Dynamics

8.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Medication

8.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Severity

8.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

8.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country

8.5.6.1. Brazil

8.5.6.2. Argentina

8.5.6.3. Rest of South America

8.6. Middle East and Africa

8.6.1. Introduction

8.6.2. Key Region-Specific Dynamics

8.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Medication

8.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Severity

8.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

9. COMPETITIVE LANDSCAPE AND MARKET POSITIONING

9.1. Competitive Overview and Key Market Players

- 9.2. Market Share Analysis and Positioning Matrix
- 9.3. Strategic Partnerships, Mergers & Acquisitions
- 9.4. Key Developments in Product Portfolios and Innovations
- 9.5. Company Benchmarking

10. COMPANY PROFILES

- 10.1. Amgen Inc.*
 - 10.1.1. Company Overview
 - 10.1.2. Product Portfolio
 - 10.1.2.1. Product Description
 - 10.1.2.2. Product Key Performance Indicators (KPIs)
 - 10.1.2.3. Financial Overview
 - 10.1.2.4. Company Revenue
 - 10.1.3. Geographical Revenue Shares
 - 10.1.4. Revenue Forecasts
 - 10.1.5. Key Developments
 - 10.1.5.1. Mergers & Acquisitions
 - 10.1.5.2. Key Product Development Activities
 - 10.1.5.3. Regulatory Approvals, etc.
 - 10.1.5.4. SWOT Analysis
- 10.2. Immunovant, Inc.
- 10.3. Viridian Therapeutics, Inc.
- 10.4. argenx
- 10.5. Tourmaline Bio, Inc.
- 10.6. F. Hoffmann-La Roche Ltd
- 10.7. Sling Therapeutics (LIST NOT EXHAUSTIVE)

11. ASSUMPTIONS AND RESEARCH METHODOLOGY

- 11.1. Data Collection Methods
- 11.2. Data Triangulation
- 11.3. Forecasting Techniques
- 11.4. Data Verification and Validation

12. APPENDIX

- 12.1. About Us and Services
- 12.2. Contact Us

List Of Tables

LIST OF TABLES

Table 1 Global Graves Ophthalmopathy Treatment Market Value, By Medication, 2025, 2029 & 2033 (US\$ Billion)

Table 2 Global Graves Ophthalmopathy Treatment Market Value, By Disease Severity, 2025, 2029 & 2033 (US\$ Billion)

Table 3 Global Graves Ophthalmopathy Treatment Market Value, By End-User, 2025, 2029 & 2033 (US\$ Billion)

Table 4 Global Graves Ophthalmopathy Treatment Market Value, By Region, 2025, 2029 & 2033 (US\$ Billion)

Table 5 Global Graves Ophthalmopathy Treatment Market Value, By Medication, 2025, 2029 & 2033 (US\$ Billion)

Table 6 Global Graves Ophthalmopathy Treatment Market Value, By Medication, 2022-2033 (US\$ Billion)

Table 7 Global Graves Ophthalmopathy Treatment Market Value, By Disease Severity, 2025, 2029 & 2033 (US\$ Billion)

Table 8 Global Graves Ophthalmopathy Treatment Market Value, By Disease Severity, 2022-2033 (US\$ Billion)

Table 9 Global Graves Ophthalmopathy Treatment Market Value, By End-User, 2025, 2029 & 2033 (US\$ Billion)

Table 10 Global Graves Ophthalmopathy Treatment Market Value, By End-User, 2022-2033 (US\$ Billion)

Table 11 Global Graves Ophthalmopathy Treatment Market Value, By Region, 2025, 2029 & 2033 (US\$ Billion)

Table 12 Global Graves Ophthalmopathy Treatment Market Value, By Region, 2022-2033 (US\$ Billion)

Table 13 North America Graves Ophthalmopathy Treatment Market Value, By Medication, 2022-2033 (US\$ Billion)

Table 14 North America Graves Ophthalmopathy Treatment Market Value, By Disease Severity, 2022-2033 (US\$ Billion)

Table 15 North America Graves Ophthalmopathy Treatment Market Value, By End-User, 2022-2033 (US\$ Billion)

Table 16 North America Graves Ophthalmopathy Treatment Market Value, By Country, 2022-2033 (US\$ Billion)

Table 17 Europe Graves Ophthalmopathy Treatment Market Value, By Medication, 2022-2033 (US\$ Billion)

Table 18 Europe Graves Ophthalmopathy Treatment Market Value, By Disease

Severity, 2022-2033 (US\$ Billion)

Table 19 Europe Graves Ophthalmopathy Treatment Market Value, By End-User, 2022-2033 (US\$ Billion)

Table 20 Europe Graves Ophthalmopathy Treatment Market Value, By Country, 2022-2033 (US\$ Billion)

Table 21 Asia-Pacific Graves Ophthalmopathy Treatment Market Value, By Medication, 2022-2033 (US\$ Billion)

Table 22 Asia-Pacific Graves Ophthalmopathy Treatment Market Value, By Disease Severity, 2022-2033 (US\$ Billion)

Table 23 Asia-Pacific Graves Ophthalmopathy Treatment Market Value, By End-User, 2022-2033 (US\$ Billion)

Table 24 Asia-Pacific Graves Ophthalmopathy Treatment Market Value, By Country, 2022-2033 (US\$ Billion)

Table 25 South America Graves Ophthalmopathy Treatment Market Value, By Medication, 2022-2033 (US\$ Billion)

Table 26 South America Graves Ophthalmopathy Treatment Market Value, By Disease Severity, 2022-2033 (US\$ Billion)

Table 27 South America Graves Ophthalmopathy Treatment Market Value, By End-User, 2022-2033 (US\$ Billion)

Table 28 South America Graves Ophthalmopathy Treatment Market Value, By Country, 2022-2033 (US\$ Billion)

Table 29 Middle East and Africa Graves Ophthalmopathy Treatment Market Value, By Medication, 2022-2033 (US\$ Billion)

Table 30 Middle East and Africa Graves Ophthalmopathy Treatment Market Value, By Disease Severity, 2022-2033 (US\$ Billion)

Table 31 Middle East and Africa Graves Ophthalmopathy Treatment Market Value, By End-User, 2022-2033 (US\$ Billion)

Table 32 Middle East and Africa Graves Ophthalmopathy Treatment Market Value, By Country, 2022-2033 (US\$ Billion)

Table 33 Amgen Inc.: Overview

Table 34 Amgen Inc.: Product Portfolio

Table 35 Amgen Inc.: Key Developments

Table 36 Immunovant, Inc.: Overview

Table 37 Immunovant, Inc.: Product Portfolio

Table 38 Immunovant, Inc.: Key Developments

Table 39 Viridian Therapeutics, Inc.: Overview

Table 40 Viridian Therapeutics, Inc.: Product Portfolio

Table 41 Viridian Therapeutics, Inc.: Key Developments

Table 42 argenx: Overview

Table 43 argenx: Product Portfolio
Table 44 argenx: Key Developments
Table 45 Tourmaline Bio, Inc.: Overview
Table 46 Tourmaline Bio, Inc.: Product Portfolio
Table 47 Tourmaline Bio, Inc.: Key Developments
Table 48 F. Hoffmann-La Roche Ltd: Overview
Table 49 F. Hoffmann-La Roche Ltd: Product Portfolio
Table 50 F. Hoffmann-La Roche Ltd: Key Developments
Table 51 Sling Therapeutics: Overview
Table 52 Sling Therapeutics: Product Portfolio
Table 53 Sling Therapeutics: Key Developments

List Of Figures

LIST OF FIGURES

Figure 1 Global Graves Ophthalmopathy Treatment Market Value, 2022-2033 (US\$ Billion)

Figure 2 Global Graves Ophthalmopathy Treatment Market Share, By Medication, 2024 & 2033 (%)

Figure 3 Global Graves Ophthalmopathy Treatment Market Share, By Disease Severity, 2024 & 2033 (%)

Figure 4 Global Graves Ophthalmopathy Treatment Market Share, By End-User, 2024 & 2033 (%)

Figure 5 Global Graves Ophthalmopathy Treatment Market Share, By Region, 2024 & 2033 (%)

Figure 6 Global Graves Ophthalmopathy Treatment Market Y-o-Y Growth, By Medication, 2023-2033 (%)

Figure 7 Monoclonal Antibodies Graves Ophthalmopathy Treatment Market Value, 2022-2033 (US\$ Billion)

Figure 8 Corticosteroids Graves Ophthalmopathy Treatment Market Value, 2022-2033 (US\$ Billion)

Figure 9 Antithyroid Medications Graves Ophthalmopathy Treatment Market Value, 2022-2033 (US\$ Billion)

Figure 10 Others Graves Ophthalmopathy Treatment Market Value, 2022-2033 (US\$ Billion)

Figure 11 Global Graves Ophthalmopathy Treatment Market Y-o-Y Growth, By Disease Severity, 2023-2033 (%)

Figure 12 Mild Disease Severity in Global Graves Ophthalmopathy Treatment Market Value, 2022-2033 (US\$ Billion)

Figure 13 Moderate Disease Severity in Global Graves Ophthalmopathy Treatment Market Value, 2022-2033 (US\$ Billion)

Figure 14 Severe Disease Severity in Global Graves Ophthalmopathy Treatment Market Value, 2022-2033 (US\$ Billion)

Figure 15 Global Graves Ophthalmopathy Treatment Market Y-o-Y Growth, By End-User, 2023-2033 (%)

Figure 16 Hospitals End-User in Global Graves Ophthalmopathy Treatment Market Value, 2022-2033 (US\$ Billion)

Figure 17 Specialty Clinics End-User in Global Graves Ophthalmopathy Treatment Market Value, 2022-2033 (US\$ Billion)

Figure 18 Academic and Research Institutes End-User in Global Graves

Ophthalmopathy Treatment Market Value, 2022-2033 (US\$ Billion)

Figure 19 Others End-User in Global Graves Ophthalmopathy Treatment Market Value, 2022-2033 (US\$ Billion)

Figure 20 Global Graves Ophthalmopathy Treatment Market Y-o-Y Growth, By Region, 2023-2033 (%)

Figure 21 North America Graves Ophthalmopathy Treatment Market Value, 2022-2033 (US\$ Billion)

Figure 22 North America Graves Ophthalmopathy Treatment Market Share, By Medication, 2024 & 2033 (%)

Figure 23 North America Graves Ophthalmopathy Treatment Market Share, By Disease Severity, 2024 & 2033 (%)

Figure 24 North America Graves Ophthalmopathy Treatment Market Share, By End-User, 2024 & 2033 (%)

Figure 25 North America Graves Ophthalmopathy Treatment Market Share, By Country, 2024 & 2033 (%)

Figure 26 Europe Graves Ophthalmopathy Treatment Market Value, 2022-2033 (US\$ Billion)

Figure 27 Europe Graves Ophthalmopathy Treatment Market Share, By Medication, 2024 & 2033 (%)

Figure 28 Europe Graves Ophthalmopathy Treatment Market Share, By Disease Severity, 2024 & 2033 (%)

Figure 29 Europe Graves Ophthalmopathy Treatment Market Share, By End-User, 2024 & 2033 (%)

Figure 30 Europe Graves Ophthalmopathy Treatment Market Share, By Country, 2024 & 2033 (%)

Figure 31 Asia-Pacific Graves Ophthalmopathy Treatment Market Value, 2022-2033 (US\$ Billion)

Figure 32 Asia-Pacific Graves Ophthalmopathy Treatment Market Share, By Medication, 2024 & 2033 (%)

Figure 33 Asia-Pacific Graves Ophthalmopathy Treatment Market Share, By Disease Severity, 2024 & 2033 (%)

Figure 34 Asia-Pacific Graves Ophthalmopathy Treatment Market Share, By End-User, 2024 & 2033 (%)

Figure 35 Asia-Pacific Graves Ophthalmopathy Treatment Market Share, By Country, 2024 & 2033 (%)

Figure 36 South America Graves Ophthalmopathy Treatment Market Value, 2022-2033 (US\$ Billion)

Figure 37 South America Graves Ophthalmopathy Treatment Market Share, By Medication, 2024 & 2033 (%)

Figure 38 South America Graves Ophthalmopathy Treatment Market Share, By Disease Severity, 2024 & 2033 (%)

Figure 39 South America Graves Ophthalmopathy Treatment Market Share, By End-User, 2024 & 2033 (%)

Figure 40 South America Graves Ophthalmopathy Treatment Market Share, By Country, 2024 & 2033 (%)

Figure 41 Middle East and Africa Graves Ophthalmopathy Treatment Market Value, 2022-2033 (US\$ Billion)

Figure 42 Middle East and Africa Graves Ophthalmopathy Treatment Market Share, By Medication, 2024 & 2033 (%)

Figure 43 Middle East and Africa Graves Ophthalmopathy Treatment Market Share, By Disease Severity, 2024 & 2033 (%)

Figure 44 Middle East and Africa Graves Ophthalmopathy Treatment Market Share, By End-User, 2024 & 2033 (%)

Figure 45 Amgen Inc.: Financials

Figure 46 Immunovant, Inc.: Financials

Figure 47 Viridian Therapeutics, Inc.: Financials

Figure 48 argenx: Financials

Figure 49 Tourmaline Bio, Inc.: Financials

Figure 50 F. Hoffmann-La Roche Ltd: Financials

Figure 51 Sling Therapeutics: Financials

I would like to order

Product name: Global Graves Ophthalmopathy Treatment Market - 2025 -2033

Product link: <https://marketpublishers.com/r/G4AB36F4B952EN.html>

Price: US\$ 4,350.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G4AB36F4B952EN.html>